Annals of Allergy Asthma & Immunology最新文献_第3页

Identifying patients with uncontrolled asthma or severe asthma 鉴别不受控制的哮喘或严重哮喘患者

IF 5.8 2区医学

Annals of Allergy Asthma & Immunology Pub Date : 2025-06-26 DOI: 10.1016/j.anai.2025.05.002

Jerrius Jubran DO , Jonathan S. Tam MD

引用次数: 0

“Allergy Shots: The Board Game” “过敏注射：棋盘游戏”

IF 5.8 2区医学

Annals of Allergy Asthma & Immunology Pub Date : 2025-06-26 DOI: 10.1016/j.anai.2025.01.012

Erin L. Reigh MD, MS

引用次数: 0

10 things to know about chronic rhinosinusitis. 关于慢性鼻窦炎要知道的10件事。

IF 5.8 2区医学

Annals of Allergy Asthma & Immunology Pub Date : 2025-06-25 DOI: 10.1016/j.anai.2025.06.008

Edsel M Abud, Soeng H Cho, John B Hagan, Dana Wallace, Blanka Kaplan, David Rose, Andrew A White

引用次数: 0

New Treatments in Atopic Dermatitis Update. 特应性皮炎的新疗法更新。

IF 5.8 2区医学

Annals of Allergy Asthma & Immunology Pub Date : 2025-06-23 DOI: 10.1016/j.anai.2025.06.020

Kennedy Gallagher, Sofia Halperin-Goldstein, Amy S Paller

{"title":"New Treatments in Atopic Dermatitis Update.","authors":"Kennedy Gallagher, Sofia Halperin-Goldstein, Amy S Paller","doi":"10.1016/j.anai.2025.06.020","DOIUrl":"https://doi.org/10.1016/j.anai.2025.06.020","url":null,"abstract":"This review evaluates the efficacy and safety of novel and emerging topical and systemic therapies for atopic dermatitis (AD) across pediatric and adult populations with an emphasis on recent advancements and future directions. Data were sourced from peer-reviewed publications (PubMed), scientific meeting abstracts, ClinicalTrials.gov, and industry press releases. Several new agents have received Food and Drug Administration approval, expanding therapeutic options for patients. Non-steroidal topical treatments, such as roflumilast and tapinarof creams, are approved for adults and children down to 6 and 2 years, respectively. Topical Janus kinase (JAK) inhibitors, including ruxolitinib, leverage inhibition of the JAK1 pathway with low concern for toxicity. The use of biologics targeting the interleukin (IL)-4/IL-13 pathway has expanded; dupilumab is approved for patients 6 months and older and tralokinumab and lebrikizumab are approved for 12 years and above. Most recently, nemolizumab, targeting the IL-31 receptor, which mediates nonhistaminergic itch, has been approved for those 12 years and above. Although baricitinib is approved in Europe and Japan, upadacitinib and abrocitinib remain the only oral JAK inhibitors approved for U.S. patients 12 years and older. Promising investigational therapies, particularly through topically altering the microbiome (bacteriotherapy) and systemic agents targeting the OX40/OX40L pathway and multispecific antibodies, are in development. These innovations represent a shift toward personalized AD management. As the treatment landscape evolves, ongoing research is essential to assess long-term safety and efficacy, as well as to develop predictive models that optimize treatment strategies, ultimately improving patient outcomes and quality of life.","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities. 曲仑单抗治疗特应性合并症患者中重度特应性皮炎的疗效

IF 5.8 2区医学

Annals of Allergy Asthma & Immunology Pub Date : 2025-06-22 DOI: 10.1016/j.anai.2025.06.022

Amy S Paller, Weily Soong, Mark Boguniewicz, Bob Geng, Jacob P Thyssen, Niels Bennike, Shannon Schneider, Andreas Wollenberg

{"title":"Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities.","authors":"Amy S Paller, Weily Soong, Mark Boguniewicz, Bob Geng, Jacob P Thyssen, Niels Bennike, Shannon Schneider, Andreas Wollenberg","doi":"10.1016/j.anai.2025.06.022","DOIUrl":"10.1016/j.anai.2025.06.022","url":null,"abstract":"Background: Atopic dermatitis (AD) is known to be associated with other atopic comorbidities that all involve type 2 immune dysregulation. Tralokinumab is a monoclonal antibody that specifically targets interleukin-13. As comorbid atopic disease could indicate a more severe AD phenotype, it is important to assess the effect of tralokinumab treatment in patients with these comorbidities.Objective: To assess the efficacy and safety of tralokinumab treatment for AD in adult and adolescent patients with moderate-to-severe AD with and without a patient-reported history of atopic comorbidities at baseline, using data from the placebo-controlled trials (ECZema TRAlokinumab) ECZTRA 1, ECZTRA 2, ECZTRA 3, and ECZTRA 6.Methods: In this post hoc analysis, subgroups were defined by a history of patient-reported asthma, food allergy, hay fever, and/or allergic conjunctivitis. End points included greater than or equal to 75% improvement in Eczema Area and Severity Index-75, Investigator's Global Assessment score of 0 or 1, and adverse events at week 16.Results: At baseline, patients with a history of at least 1 atopic comorbidity exhibited more severe disease than patients with no atopic comorbidities. At week 16, higher proportions of adult and adolescent patients receiving tralokinumab vs placebo achieved Eczema Area and Severity Index-75 and Investigator's Global Assessment score of 0 or 1, regardless of the presence of atopic comorbidities at baseline. Most adverse events were of mild or moderate severity.Conclusion: Regardless of the presence or number of self-reported atopic comorbidities, 16 weeks of tralokinumab treatment improved AD severity in adults and adolescents.Trial registration: ClinicalTrials.gov Identifiers: ECZTRA 1 (NCT03131648); ECZTRA 2 (NCT03160885); ECZTRA 3 (NCT03363854); and ECZTRA 6 (NCT03526861).","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144486825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

10 ways to Improve Emergency Preparedness for Allergic Patients While Flying. 10种方法提高飞机过敏患者的应急准备。

IF 5.8 2区医学

Annals of Allergy Asthma & Immunology Pub Date : 2025-06-22 DOI: 10.1016/j.anai.2025.06.025

Sangeetha M Kodoth, Niraj C Patel, Hyun J Park, Joel P Brooks

引用次数: 0

National Asthma Control Program: Funding simple, effective strategies to reduce the asthma burden and costs. 国家哮喘控制计划：资助简单、有效的策略以减少哮喘负担和费用。

IF 5.8 2区医学

Annals of Allergy Asthma & Immunology Pub Date : 2025-06-22 DOI: 10.1016/j.anai.2025.06.027

Waleed Omar, Paige Hardy, Andrea A Pappalardo

引用次数: 0

Outcomes of aspirin allergy evaluation in cardiac patients presenting with non-ST-elevation myocardial infarction. 非st段抬高型心肌梗死患者阿司匹林过敏评价的结果

IF 5.8 2区医学

Annals of Allergy Asthma & Immunology Pub Date : 2025-06-21 DOI: 10.1016/j.anai.2025.06.023

Sarah S Han, Ryan Wilson, Ellen Liu, Lauren Hassen, Monica T Kraft

引用次数: 0

Evaluation of the PEN-FAST clinical decision rule in non-beta-lactam antibiotic allergy assessment. PEN-FAST临床决策准则在非β -内酰胺类抗生素过敏评价中的应用

IF 5.8 2区医学

Annals of Allergy Asthma & Immunology Pub Date : 2025-06-21 DOI: 10.1016/j.anai.2025.06.019

Deniz Göcebe, Elham Khatamzas, Alexander Enk, Knut Schäkel

{"title":"Evaluation of the PEN-FAST clinical decision rule in non-beta-lactam antibiotic allergy assessment.","authors":"Deniz Göcebe, Elham Khatamzas, Alexander Enk, Knut Schäkel","doi":"10.1016/j.anai.2025.06.019","DOIUrl":"10.1016/j.anai.2025.06.019","url":null,"abstract":"Background: False antibiotic allergy labels lead to the unnecessary use of broad-spectrum agents, contributing to antimicrobial resistance and poorer clinical outcomes. Penicillin allergy delabeling initiatives have been supported by validated clinical decision rules such as PEN-FAST. However, there are currently no available standardized approaches for non-beta-lactam allergies, for which standardized and validated skin tests are also lacking.Objective: First, to validate the safety and negative predictive value (NPV) of PEN-FAST for penicillin allergies. Second, to evaluate whether the performance of PEN-FAST could be replicated for non-beta-lactam antibiotic allergy labels.Methods: This retrospective single-center comparative cohort study analyzed adult patients with penicillin or non-beta-lactam allergy labels referred to our allergy division at the Department of Dermatology, Heidelberg, Germany. Allergy assessment included skin tests and subsequent drug challenge. The performance of the previously published PEN-FAST criteria was evaluated for both cohorts.Results: A total of 102 penicillin allergy and 191 non-beta-lactam labels were analyzed. Confirmed allergies were more prevalent among non-beta-lactams (50.3% vs 37.3%). PEN-FAST exhibited high sensitivity for both penicillin (97.4%) and non-beta-lactams (94.8%), with an NPV of 95.8% and 82.8%, respectively. Misclassifications were limited to mild cutaneous reactions. Excluding clindamycin labels increased the NPV for non-beta-lactams to 95%.Conclusion: Despite lower NPV for non-beta-lactam labels and varying performance across antibiotic classes, our results indicate that PEN-FAST may serve as a safe risk stratification tool for non-beta-lactam allergy labels. Prospective studies with direct drug challenges are required to assess its utility in the delabeling of non-beta-lactam allergies.","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and Phenotype of Food Allergy in Children with Cystic Fibrosis. 囊性纤维化儿童食物过敏的患病率和表型。

IF 5.8 2区医学

Annals of Allergy Asthma & Immunology Pub Date : 2025-06-21 DOI: 10.1016/j.anai.2025.06.024

Hang P Nguyen, Veronika Shabanova, Sarah McCollum, Brooke Polk, Tricia Lee, Kyle Whittington, Priscila Cunha, Emanuela M Bruscia, Marie E Egan, Marc Emmenegger, Stephanie Leeds

{"title":"Prevalence and Phenotype of Food Allergy in Children with Cystic Fibrosis.","authors":"Hang P Nguyen, Veronika Shabanova, Sarah McCollum, Brooke Polk, Tricia Lee, Kyle Whittington, Priscila Cunha, Emanuela M Bruscia, Marie E Egan, Marc Emmenegger, Stephanie Leeds","doi":"10.1016/j.anai.2025.06.024","DOIUrl":"https://doi.org/10.1016/j.anai.2025.06.024","url":null,"abstract":"Background: Nonspecific gastrointestinal symptoms associated with cystic fibrosis (CF) may be misdiagnosed as food allergy (FA). There is a paucity of data regarding prevalence and phenotype of IgE-mediated FA in CF.Objective: We aimed to determine the prevalence and characteristics of pediatric FA in CF.Methods: We conducted a retrospective pediatric cohort study using the Cystic Fibrosis Foundation Registries and electronic medical records from [redacted names A and B]. Demographic, biometric, and medical information were collected, and individuals suspected of having FA were identified through multiple inclusion criteria. A convincing FA diagnosis was established based on a priori criteria including medical history, testing results, and management. Estimated prevalence was calculated as a percentage and compared to the most recently reported pediatric FA prevalence in the United States (US).Results: Among 289 patients (51.21% male, median age=12.40 years), 11 (3.81%, 95% confidence interval [CI] 1.91-6.71) had at least one convincing FA, yielding a smaller prevalence than the most recent estimate in the US pediatric population (7.60%, 95% CI 7.10-8.10, p=0.015). Male CF patients (6.08% versus 1.42%, p=0.038) and patients without pancreatic enzyme replacement (9.09% versus 2.25%, p=0.020) had higher prevalence of convincing FA.Conclusion: Our study of pediatric CF patients found a lower prevalence of FA compared to the general pediatric population in the US. Stringent criteria should be used when labeling CF patients with FA to minimize overdiagnosis. Further studies are needed to investigate if CF could potentially be protective against the development of FA.","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":5.8,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0